With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.

Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

Today, Benzinga's options scanner spotted 20 options trades for BioNTech. This is not a typical pattern. The sentiment among these major traders is split, with 55% bullish and 20% bearish. Among all ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...